- Home
- Products
- Customized ADCs
- EGFR
- Anti-EGFR (Zalutumumab)-VC-Duostatin-3 ADC
Anti-EGFR (Zalutumumab)-VC-Duostatin-3 ADC (CAT#: ADC-W-531)
This ADC product is comprised of an anti-EGFR monoclonal antibody (Trastuzumab) conjugated via a VC linker to Duostatin-3. The Duostatin-3 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Duostatin-3 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- EGFR
- Alternative Names
- epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian
- Target Entrez Gene ID
- 1956
- Target UniProt ID
- P00533
- Overview
- The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene.
- Overview
- Anti-EGFR lgG1 Antibody, Zalutumumab
- Generic name
- Zalutumumab
- Species Reactivity
- Human
- Name
- VC (valine-citrulline)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- Duostatin-3
- Description
- Duostatin-3 is an antimitotic agent that inhibits cell division by blocking of tubulin polymerization. Unlike vcMMAE, duostatin-3 cannot kill neighboring tumor cells when the drug is released from the antibody.
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-531. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2592 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-504 | Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
| ADC-W-2593 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-496 | Anti-EGFR-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-564 | Anti-MUC16-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-475 | Anti-CA9-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-494 | Anti-SLC39A6-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-AA-048 | Protein G-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-462 | Anti-GPNMB-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-530 | Anti-ERBB2(Trastuzumab)-VC-Duostatin-3 ADC | VC (valine-citrulline) | Duostatin-3 |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2064)
- Anti-MS4A1 (Ocrelizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1574)
- Anti-CD4 (Tregalizumab)-SPDB-DM4 ADC (CAT#: ADC-W-873)
- Anti-IGF1-SPDB-DM4 ADC (CAT#: ADC-W-1233)
- Anti-APP (Gantenerumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-684)
- Anti-ACVR2B (Bimagrumab)-MC-MMAF ADC (CAT#: ADC-W-652)
- Anti-LTA (Pateclizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1533)
- Anti-B-cell lymphomas (Detumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2185)
- Anti-IL6-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1433)
- Anti-C. diff toxin B (Bezlotoxumab)-SMCC-DM1 ADC (CAT#: ADC-W-2060)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
